CompaniesInvestorsPeople
Home
Loading

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

Get in Touch

  • Contact

  • Request a Demo

  • Request Data Updates

  • Add a Company

Research

  • Companies

  • Investors

  • People

aVenture

  • Download App

  • Pricing

Download the aVenture Research beta for iOS and iPadOSDownload aVenture Research on the Mac App Store

Resources

  • Documentation

  • Use Cases

  • CLI

  • MCP

  • Feature Requests

  • Sitemap

Member

Backed by

Ask AI about aVenture

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy · Terms of Service

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading
Home›
Companies›
Kintsugi›
Analysis
Kintsugi logo

Kintsugi

Operating Status: Closed

Kintsugi: Award-winning AI software detecting depression and anxiety through voice biomarkers.

Berkeley, CA, US🇺🇸
Founded
2019
Accelerator
Techstars logoTechstars: UnitedHealthcare2020
Loading
Overview
Analysis
Compare
Fundraising
Employees
News
Library

Contents

  1. 01Competitive Strengths
  2. 02Market Outlook
  3. 03Executive Summary
  4. 04Products & Services
  1. 01Competitive Strengths
  2. 02Market Outlook
  3. 03Executive Summary
  4. 04Products & Services

Competitive Advantages

Kintsugi Voice technology was evaluated in a peer-reviewed study published in the Annals of Family Medicine in January 2025.

The study assessed the efficacy of the Kintsugi Voice v1 machine learning technology to detect depression and anxiety from short clips of free-form speech, providing clinical validation for the voice biomarker approach.

Source: annfammed.org

Market Outlook

The mental health technology market is experiencing significant growth driven by increasing awareness of mental health conditions and demand for accessible screening tools.

Voice biomarker technology represents an emerging category of non-invasive diagnostic tools that can integrate into existing healthcare infrastructure. Regulatory challenges including FDA clearance requirements have proven significant barriers for clinical AI startups in this space.

Source: forbes.com

Memo

Multiple independent sources from February 2026 establish that Kintsugi Mindful Wellness, Inc. ceased commercial operations with no acquisition, merger, or sale to any other party. The shutdown was driven by the unsustainable costs and timelines of U.S. FDA regulatory clearance for a venture-backed business model in clinical mental health AI.

The company chose to open-source its voice biomarker models, methodologies, and research as a gift to the global mental health community rather than pursue a sale or continuation. Coverage from the official company blog, Healthcare IT News, Forbes, Behavioral Health Business, and founder Grace Chang's LinkedIn announcement uniformly describes an independent wind-down with no mention of a buyer or acquirer. This constitutes source-backed evidence for acquisitionsUnobtainable.

Source: kintsugihealth.com

Product Overview

Kintsugi Voice is an API-first platform that uses voice biomarkers in speech to identify, prioritize, and care for mental health in real time.

The technology detects signs of depression and anxiety from short clips of free-form speech. Kintsugi Connect enables seamless integration into existing healthcare workflows for providers and insurers.

Source: kintsugihealth.com